Business
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND 2021 YEAR END RESULTS, FILING OF ITS 2021 AIF, AND OPERATIONAL UPDATE
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND 2021 YEAR END RESULTS, FILING OF ITS 2021 A...
About this update from Atlas Energy Corp.
[{"type":"text","content":"\n \n \n \n WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND 2021 YEAR END RESULTS, FILING OF ITS 2021 AIF, AND OPERATIONAL UPDATE\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n VANCOUVER, BC\n \n \n ,\n \n \n March 29, 2022\n \n \n /CNW/ - Willow Biosciences Inc. (\"\n \n Willow\n \n \" or the \"\n \n Company\n \n \") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company that develops technology to manufacture pure, consistent and sustainable compounds\n \n via\n \n yeast biosynthesis, is pleased to announce its financial and operating results for the three months and year ended\n \n December 31, 2021\n \n , and filing of its Annual Information Form (\"AIF\"). Selected financial and operational information is outlined below and should be read with Willow's audited consolidated financial statements (the \"Financial Statements\") and management's discussion and analysis (the \"MD&A\") as of\n \n December 31, 2021\n \n , which are available on SEDAR at\n \n \n www.sedar.com\n \n \n and on Willow's website at\n \n \n www.willowbio.com\n \n \n .\n \n \n \n \n \n \n \n \n \n \n Statement from the CEO\n \n \n \n \"2021 was both an exciting and challenging year for Willow\", said\n \n Trevor Peters\n \n , Willow's President and Chief Executive Officer. \"The progress that we continue to make building out our core platform technology is setting the company up to be a leader in the bio revolution that is unfolding around us. While our platform build out is on schedule, the market for cannabinoids, the company's first group of compounds, has seen headwinds due to the lack of clarity around the regulatory future of cannabis, predominantly in\n \n the United States\n \n . This is causing larger consumer companies to remain on the sidelines until more certainty is given by lawmakers. Willow management believes this to only be temporary, given the bipartisan support, for instance, seen in\n \n the United States\n \n toward decriminalization and ultimate legalization. The message for our stakeholders in 2022 is that we w...